2
|
Khan AB, Carpenter B, Santos e Sousa P, Pospori C, Khorshed R, Griffin J, Velica P, Zech M, Ghorashian S, Forrest C, Thomas S, Gonzalez Anton S, Ahmadi M, Holler A, Flutter B, Ramirez-Ortiz Z, Means TK, Bennett CL, Stauss H, Morris E, Lo Celso C, Chakraverty R. Redirection to the bone marrow improves T cell persistence and antitumor functions. J Clin Invest 2018; 128:2010-2024. [PMID: 29485974 PMCID: PMC5919805 DOI: 10.1172/jci97454] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2017] [Accepted: 02/20/2018] [Indexed: 12/13/2022] Open
Abstract
A key predictor for the success of gene-modified T cell therapies for cancer is the persistence of transferred cells in the patient. The propensity of less differentiated memory T cells to expand and survive efficiently has therefore made them attractive candidates for clinical application. We hypothesized that redirecting T cells to specialized niches in the BM that support memory differentiation would confer increased therapeutic efficacy. We show that overexpression of chemokine receptor CXCR4 in CD8+ T cells (TCXCR4) enhanced their migration toward vascular-associated CXCL12+ cells in the BM and increased their local engraftment. Increased access of TCXCR4 to the BM microenvironment induced IL-15-dependent homeostatic expansion and promoted the differentiation of memory precursor-like cells with low expression of programmed death-1, resistance to apoptosis, and a heightened capacity to generate polyfunctional cytokine-producing effector cells. Following transfer to lymphoma-bearing mice, TCXCR4 showed a greater capacity for effector expansion and better tumor protection, the latter being independent of changes in trafficking to the tumor bed or local out-competition of regulatory T cells. Thus, redirected homing of T cells to the BM confers increased memory differentiation and antitumor immunity, suggesting an innovative solution to increase the persistence and functions of therapeutic T cells.
Collapse
Affiliation(s)
- Anjum B. Khan
- University College London (UCL) Cancer Institute, London, United Kingdom
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Ben Carpenter
- University College London (UCL) Cancer Institute, London, United Kingdom
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Pedro Santos e Sousa
- University College London (UCL) Cancer Institute, London, United Kingdom
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Constandina Pospori
- Department of Life Sciences, Imperial College London, London, United Kingdom
| | - Reema Khorshed
- Department of Life Sciences, Imperial College London, London, United Kingdom
| | - James Griffin
- University College London (UCL) Cancer Institute, London, United Kingdom
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Pedro Velica
- University College London (UCL) Cancer Institute, London, United Kingdom
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Mathias Zech
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Sara Ghorashian
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Calum Forrest
- University College London (UCL) Cancer Institute, London, United Kingdom
| | - Sharyn Thomas
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Sara Gonzalez Anton
- Department of Life Sciences, Imperial College London, London, United Kingdom
| | - Maryam Ahmadi
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Angelika Holler
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Barry Flutter
- University College London (UCL) Cancer Institute, London, United Kingdom
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Zaida Ramirez-Ortiz
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, Massachusetts, USA
| | - Terry K. Means
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, Massachusetts, USA
| | - Clare L. Bennett
- University College London (UCL) Cancer Institute, London, United Kingdom
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Hans Stauss
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Emma Morris
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| | - Cristina Lo Celso
- Department of Life Sciences, Imperial College London, London, United Kingdom
- The Francis Crick Institute, London, United Kingdom
| | - Ronjon Chakraverty
- University College London (UCL) Cancer Institute, London, United Kingdom
- UCL Institute of Immunity and Transplantation, London, United Kingdom
| |
Collapse
|
3
|
Santos e Sousa P, Ciré S, Conlan T, Jardine L, Tkacz C, Ferrer IR, Lomas C, Ward S, West H, Dertschnig S, Blobner S, Means TK, Henderson S, Kaplan DH, Collin M, Plagnol V, Bennett CL, Chakraverty R. Peripheral tissues reprogram CD8+ T cells for pathogenicity during graft-versus-host disease. JCI Insight 2018; 3:97011. [PMID: 29515032 PMCID: PMC5922296 DOI: 10.1172/jci.insight.97011] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Accepted: 02/07/2018] [Indexed: 01/05/2023] Open
Abstract
Graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic stem cell transplantation induced by the influx of donor-derived effector T cells (TE) into peripheral tissues. Current treatment strategies rely on targeting systemic T cells; however, the precise location and nature of instructions that program TE to become pathogenic and trigger injury are unknown. We therefore used weighted gene coexpression network analysis to construct an unbiased spatial map of TE differentiation during the evolution of GVHD and identified wide variation in effector programs in mice and humans according to location. Idiosyncrasy of effector programming in affected organs did not result from variation in T cell receptor repertoire or the selection of optimally activated TE. Instead, TE were reprogrammed by tissue-autonomous mechanisms in target organs for site-specific proinflammatory functions that were highly divergent from those primed in lymph nodes. In the skin, we combined the correlation-based network with a module-based differential expression analysis and showed that Langerhans cells provided in situ instructions for a Notch-dependent T cell gene cluster critical for triggering local injury. Thus, the principal determinant of TE pathogenicity in GVHD is the final destination, highlighting the need for target organ-specific approaches to block immunopathology while avoiding global immune suppression.
Collapse
MESH Headings
- Animals
- Antigens, CD/genetics
- Antigens, CD/metabolism
- Antigens, Surface/genetics
- Antigens, Surface/metabolism
- Bone Marrow Transplantation/adverse effects
- Cells, Cultured
- Cellular Reprogramming/genetics
- Cellular Reprogramming/immunology
- Disease Models, Animal
- Female
- Gene Expression Regulation/immunology
- Graft vs Host Disease/immunology
- Graft vs Host Disease/pathology
- Hematopoietic Stem Cell Transplantation/adverse effects
- Humans
- Langerhans Cells/immunology
- Langerhans Cells/metabolism
- Lectins, C-Type/genetics
- Lectins, C-Type/metabolism
- Male
- Mannose-Binding Lectins/genetics
- Mannose-Binding Lectins/metabolism
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Multigene Family/genetics
- Multigene Family/immunology
- Primary Cell Culture
- Receptors, Notch/metabolism
- Skin/cytology
- Skin/immunology
- Skin/pathology
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Cytotoxic/metabolism
- Transplantation Chimera
- Transplantation, Homologous/adverse effects
Collapse
Affiliation(s)
- Pedro Santos e Sousa
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| | - Séverine Ciré
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| | - Thomas Conlan
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| | - Laura Jardine
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
| | | | - Ivana R. Ferrer
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| | - Cara Lomas
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| | - Sophie Ward
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| | - Heather West
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| | - Simone Dertschnig
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| | - Sven Blobner
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| | - Terry K. Means
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, Massachusetts, USA
| | | | - Daniel H. Kaplan
- Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Matthew Collin
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
| | | | - Clare L. Bennett
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| | - Ronjon Chakraverty
- Haematology, UCL Cancer Institute and Institute of Immunity & Transplantation, London, United Kingdom (UK)
| |
Collapse
|
5
|
D’Aveni M, Rossignol J, Coman T, Sivakumaran S, Henderson S, Manzo T, Santos e Sousa P, Bruneau J, Fouquet G, Zavala F, Alegria-Prévot O, Garfa-Traoré M, Suarez F, Trebeden-Nègre H, Mohty M, Bennett CL, Chakraverty R, Hermine O, Rubio MT. G-CSF mobilizes CD34
+
regulatory monocytes that inhibit graft-versus-host disease. Sci Transl Med 2015; 7. [DOI: 10.1126/scitranslmed.3010435] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Abstract
G-SCF–mobilized CD34
+
monocytes inhibit graft-versus-host disease by the production of nitric oxide and the induction of regulatory T cells.
Collapse
Affiliation(s)
- Maud D’Aveni
- INSERM U1163 and CNRS ERL 8254, Faculté de Médecine, Université Paris Descartes, Hôpital Necker, 75015 Paris, France
- Faculté de Médecine and Université Paris-Sud, 94805 Villejuif, France
- Institut Hospitalo-Universitaire Imagine, Université Sorbonne Paris Cité, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - Julien Rossignol
- INSERM U1163 and CNRS ERL 8254, Faculté de Médecine, Université Paris Descartes, Hôpital Necker, 75015 Paris, France
- Faculté de Médecine and Université Paris-Sud, 94805 Villejuif, France
- Institut Hospitalo-Universitaire Imagine, Université Sorbonne Paris Cité, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - Tereza Coman
- INSERM U1163 and CNRS ERL 8254, Faculté de Médecine, Université Paris Descartes, Hôpital Necker, 75015 Paris, France
- Faculté de Médecine and Université Paris-Sud, 94805 Villejuif, France
- Institut Hospitalo-Universitaire Imagine, Université Sorbonne Paris Cité, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - Shivajanani Sivakumaran
- Institute of Immunity and Transplantation, University College London, London NW3 2PF, UK
- Cancer Institute, University College London, London WC1E 6DD, UK
| | | | - Teresa Manzo
- Institute of Immunity and Transplantation, University College London, London NW3 2PF, UK
- Cancer Institute, University College London, London WC1E 6DD, UK
| | - Pedro Santos e Sousa
- Institute of Immunity and Transplantation, University College London, London NW3 2PF, UK
- Cancer Institute, University College London, London WC1E 6DD, UK
| | - Julie Bruneau
- INSERM U1163 and CNRS ERL 8254, Faculté de Médecine, Université Paris Descartes, Hôpital Necker, 75015 Paris, France
- Institut Hospitalo-Universitaire Imagine, Université Sorbonne Paris Cité, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
- Laboratoire d’anatomopathologie, Groupe Hospitalier Necker–Enfants Malades, 75015 Paris, France
| | - Guillemette Fouquet
- INSERM U1163 and CNRS ERL 8254, Faculté de Médecine, Université Paris Descartes, Hôpital Necker, 75015 Paris, France
- Faculté de Médecine and Université Paris-Sud, 94805 Villejuif, France
- Institut Hospitalo-Universitaire Imagine, Université Sorbonne Paris Cité, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - Flora Zavala
- INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades, Université Paris Descartes, 75015 Paris, France
| | - Olinda Alegria-Prévot
- INSERM U1163 and CNRS ERL 8254, Faculté de Médecine, Université Paris Descartes, Hôpital Necker, 75015 Paris, France
| | - Meriem Garfa-Traoré
- Institut Fédératif de Recherche 94 Plateforme d’Imagerie Cellulaire, Faculté de Médecine, Université Paris Descartes, Hôpital Necker, 75015 Paris, France
| | - Felipe Suarez
- Service d’Hématologie Clinique, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - Hélène Trebeden-Nègre
- Département de biothérapie, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France
| | - Mohamad Mohty
- Service d’Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France
- INSERM UMRs 938, Centre de recherche de l’hôpital Saint Antoine, 75012 Paris, France
- Université Pierre et Marie Curie, Paris VI, 75006 Paris, France
| | - Clare L. Bennett
- Institute of Immunity and Transplantation, University College London, London NW3 2PF, UK
- Cancer Institute, University College London, London WC1E 6DD, UK
| | - Ronjon Chakraverty
- Institute of Immunity and Transplantation, University College London, London NW3 2PF, UK
- Cancer Institute, University College London, London WC1E 6DD, UK
| | - Olivier Hermine
- INSERM U1163 and CNRS ERL 8254, Faculté de Médecine, Université Paris Descartes, Hôpital Necker, 75015 Paris, France
- Institut Hospitalo-Universitaire Imagine, Université Sorbonne Paris Cité, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
- Service d’Hématologie Clinique, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - Marie-Thérèse Rubio
- INSERM U1163 and CNRS ERL 8254, Faculté de Médecine, Université Paris Descartes, Hôpital Necker, 75015 Paris, France
- Institut Hospitalo-Universitaire Imagine, Université Sorbonne Paris Cité, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
- Service d’Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France
- INSERM UMRs 938, Centre de recherche de l’hôpital Saint Antoine, 75012 Paris, France
- Université Pierre et Marie Curie, Paris VI, 75006 Paris, France
| |
Collapse
|
6
|
Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, Löffler J, Maertens JA, Bell AS, Inforzato A, Barbati E, Almeida B, Santos e Sousa P, Barbui A, Potenza L, Caira M, Rodrigues F, Salvatori G, Pagano L, Luppi M, Mantovani A, Velardi A, Romani L, Carvalho A. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med 2014; 370:421-32. [PMID: 24476432 DOI: 10.1056/nejmoa1211161] [Citation(s) in RCA: 228] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND The soluble pattern-recognition receptor known as long pentraxin 3 (PTX3) has a nonredundant role in antifungal immunity. The contribution of single-nucleotide polymorphisms (SNPs) in PTX3 to the development of invasive aspergillosis is unknown. METHODS We screened an initial cohort of 268 patients undergoing hematopoietic stem-cell transplantation (HSCT) and their donors for PTX3 SNPs modifying the risk of invasive aspergillosis. The analysis was also performed in a multicenter study involving 107 patients with invasive aspergillosis and 223 matched controls. The functional consequences of PTX3 SNPs were investigated in vitro and in lung specimens from transplant recipients. RESULTS Receipt of a transplant from a donor with a homozygous haplotype (h2/h2) in PTX3 was associated with an increased risk of infection, in both the discovery study (cumulative incidence, 37% vs. 15%; adjusted hazard ratio, 3.08; P=0.003) and the confirmation study (adjusted odds ratio, 2.78; P=0.03), as well as with defective expression of PTX3. Functionally, PTX3 deficiency in h2/h2 neutrophils, presumably due to messenger RNA instability, led to impaired phagocytosis and clearance of the fungus. CONCLUSIONS Genetic deficiency of PTX3 affects the antifungal capacity of neutrophils and may contribute to the risk of invasive aspergillosis in patients treated with HSCT. (Funded by the European Society of Clinical Microbiology and Infectious Diseases and others.).
Collapse
|